Hence, the overall response rate to pembrolizumab in unselected patients with advanced triple-negative (ie, estrogen receptor [ER]-, progesterone receptor [PR]-, and HER2-negative) breast cancers (TNBCs) was 18.5% in a multicenter, nonrandomized phase Ib clinical trial (16). This evidence concerns the gene PGR and breast carcinoma.